CROSSING OVER

This could be another watershed year for Rx-to-OTC switches.The probable conversion of ulcer treatment Prilosec is expected to bring big-time sales, while the possible changeover of emergency contraceptive Plan B is likely to generate big-time controversy.Prilosec is a top-selling ulcer treatment from drug maker AstraZeneca, London, and the company expects over-the-counter approval by the Food and

This could be another watershed year for Rx-to-OTC switches.

The probable conversion of ulcer treatment Prilosec is expected to bring big-time sales, while the possible changeover of emergency contraceptive Plan B is likely to generate big-time controversy.

Prilosec is a top-selling ulcer treatment from drug maker AstraZeneca, London, and the company expects over-the-counter approval by the Food and Drug Administration this summer. It has already received preliminary sanc

Register to view the full article